The rising incidence rate of cancer as pushed the healthcare industry to develop less invasive diagnosis and treatment options for cancer-ridden patients. Liquid biopsy has emerged as the latest breakthrough in the cancer screening and diagnostic field as it uses just a sample of blood to trace the presence of DNA from tumor cells that are in the blood. It can be a boon for the cancer healthcare industry as it helps in diagnosis of cancer at an early stage, as well as in monitoring the growth of cancer in a patient's body.

The increasing interest of scientists in nucleic acids in plasma and serum widened the spectrum of molecular diagnosis. It has provided oncology with a non-invasive method for the detection of tumor-derived genetic changes, epigenetic alterations, and viral nucleic acids, which helps in monitoring and prognosis of different types of cancer malignancies. It has also facilitated in prenatal diagnosis which is non-invasive in nature and helps in monitoring of pregnancy-associated abnormalities. Liquid biopsy is seen as a boon for the early detection of cancer, disease prognosis, treatment guidance, and to study the evolution of cancer. Researchers are seeing liquid biopsy with high hopes which can open a wide array of opportunities for cancer healthcare.

Liquid biopsy identifies specific mutations in the circulating DNA (ctDNA), found in the plasma, which may pave the way for prognosis and therapy. With the advancement in sequencing and gene-amplification technologies, liquid biopsies can access more biomarkers which will consequently help in identifying more types of cancer. The advent of next-generation sequencing (NGS) techniques has also stimulated the research works in liquid biopsy field and opened up new clinical applications. The high throughput rate of NGS, along with single-nucleotide resolution and its gradually receding costs have made NGS an increasingly and accessible and efficient method for gene expression analysis.

The global liquid biopsy market is expected to reach $4.43 billion by 2025, growing at an impressive double-digit CAGR from 2017 to 2025. The future of diagnostics market is non-invasive, hence, the demand for liquid biopsy and its products is increasing rapidly. The market is being dominated by the kits and consumables product segment, which contributed approximately 63% to the global liquid biopsy market value in 2016. This product segment will continue its dominance over the market and will account for 61% of the market value by 2025. On the basis of biomarker, the market is being dominated by Circulating Tumor Cells (CTCs), which was reported to contribute 56% to the global liquid biopsy market value in 2016. It is expected to maintain its dominance in the market and is estimated to contribute approximately 45% to the global market value in 2025.

Liquid biopsy is set to transform the oncology industry, as the clinical oncology segment has contributed highly to the global market value in 2016, and is expected to account for approximately 92% to the global liquid biopsy market value in 2025. BIS Healthcare has conducted an extensive research on global liquid biopsy market, and compiled the observations and insights in a report titled ‘Global Liquid Biopsy Market Analysis and Forecast, 2017-2025'. The market intelligence report aims at providing an in-depth analysis of the key development strategies, marketing strategies and market trend dynamics which include drivers, restraints, and opportunities prevailing in the industry.

For further queries, please write to us at sales@bisresearch.com or call us at: +1 650 228 0182.